Perceptive Advisors LLC sold $344k of LYRA
owner at Lyra Therapeutics, Inc.. 70,390 shares at an average of $4.89, traded Nov 6, 2025, filed Nov 10, 2025.
Score components
- +12Role10% owner
- +15Trade size$344k at market
- +10Share of holdings soldSold 31% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.6%, 3m -65.5%, 6m -83.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-274540, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -28,902 | $5.18 | $150k | 200,480 | Nov 10, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -3,247 | $5.18 | $17k | 22,521 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -17,746 | $4.75 | $84k | 182,734 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -1,993 | $4.75 | $9,460 | 20,528 | Nov 10, 2025 |
| Nov 10, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -16,633 | $4.54 | $76k | 166,101 | Nov 10, 2025 |
| Nov 10, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -1,869 | $4.54 | $8,485 | 18,659 | Nov 10, 2025 |
Related signals
Other insiders at Lyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $2,587 769 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $5,726 1,702 shares | -0% | |
| 34Weak | LYRAsell Lyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $183k 45,875 shares | -28% | |
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $6,094 684 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $14k 1,565 shares | -0% | |
| 39Weak | LYRAbuy Lyra Therapeutics, Inc. | Harlan Waksal Executive Chair | $74k 25,000 shares | +11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.